CAC
TEVA icon

Cowen and Company’s Teva Pharmaceuticals TEVA Stock Holding History

Cowen and Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-243,800
Closed -$55.1K – 676
2022
Q4 		$55.1K Buy
+243,800
New +$2.13M 0.01% 248
2022
Q3 		– Sell
-223,800
Closed -$94K – 762
2022
Q2 		$94K Hold
223,800
– – 0.01% 251
2022
Q1 		$214K Hold
223,800
– – 0.02% 230
2021
Q4 		$223K Buy
+223,800
New +$2.02M 0.02% 293
2020
Q4 		– Sell
-61,100
Closed -$11K – 515
2020
Q3 		$11K Buy
+61,100
New +$646K ﹤0.01% 387
2020
Q2 		– Sell
-336,500
Closed -$200K – 475
2020
Q1 		$200K Buy
+336,500
New +$3.45M 0.05% 193

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Cowen and Company's TEVA Position: Q1 2023 in Review

Cowen and Company sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 176,942 shares — an estimated $1.61M sold.

Cowen and Company first reported a position in TEVA in Q4 2021 and held it in 5 quarters. The position peaked at $1.61M in Q4 2022. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • Cowen and Company reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 176,942 Teva Pharmaceuticals shares in Q1 2023, an estimated $1.61M.
  • Cowen and Company first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Cowen and Company's Teva Pharmaceuticals position peaked at $1.61M in Q4 2022.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.